Once again we&#39;re recording from San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day two: <a href="https://www.biospace.com/article/ai-neuroscience-and-glp-1s-will-continue-to-make-headlines-expert-panel-/" target="_blank" rel="noopener noreferer">AI</a>, <a href="https://www.biospace.com/article/gene-therapy-approvals-to-ramp-up-in-2024-amid-manufacturing-cost-challenges/" target="_blank" rel="noopener noreferer">cell and gene therapy</a> innovation and pricing, and the <a href="https://www.biospace.com/article/car-t-cell-therapy-is-a-comparatively-low-risk-cancer-treatment-industry-experts-/" target="_blank" rel="noopener noreferer">risks</a> of CAR T cell therapy.
Join Lori, Greg and Tyler as they discuss what&#39;s been top of mind. 
You can <a href="https://www.biospace.com/article/jpm-2024-on-the-ground-in-san-francisco/">⁠⁠follow our coverage⁠⁠</a> as our team adds updates throughout the day.
Join us tomorrow for Day 3 highlights!

On the ground at #JPM2024 - Day 3 highlights

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.